Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals

Inclusion Criteria Patients must have: * HIV seropositivity by commercially available ELISA. * Meet Disease Status criteria. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Concurrent neoplasms other than basal cell carcinoma of the skin, in-situ carcinoma of the cervix or limited cutaneous Kaposi's sarcoma. * Recently treated HIV-related lymphoma. * Major organ allograft. * Presence of space occupying central nervous system (CNS) lesions or other conditions which would be anticipated to cause cerebral edema. * Renal compromise or use of drug therapy anticipated to lead to renal compromise. * Active opportunistic infection requiring hospitalization or exclude medication. * Requiring continual acyclovir for suppression of herpes infection. Concurrent Medication: Excluded: * Acyclovir. * Drug therapy anticipated to lead to renal compromise. Patients with the following are excluded: * Intolerance to zidovudine (AZT) at 300 mg/day divided q8h or didanosine (ddI) at 7 mg/kg/day given twice a day. * History of HIV-related lymphoma. * History of asthma requiring frequent therapy, chronic pulmonary disease, hypertension requiring therapy, or congestive heart failure. * Any of the symptoms or conditions listed in Exclusion - Co-Existing Conditions. Prior Medication: Excluded: \- Any prior therapy with interleukin-2 (IL-2) or PEG IL-2. Excluded 30 days prior to study entry: \- Treatment with other anti-HIV medication or known immunomodulators or other chemotherapy or radiation therapy. Active substance abuse so patients would be anticipated to be poorly compliant with protocol requirements.